TGCT Today: Understanding Diagnosis, Treatment, and Long-term Care

Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive disease that can cause chronic pain, joint dysfunction, reduced mobility, and significant impacts on quality of life, particularly in patients with diffuse disease. In this expert discussion, Dr William Tap and Dr Emanuela Palmerini explore the evolving management of TGCT, including the biologic role of the CSF1/CSF1R pathway, challenges in diagnosis and disease monitoring, and the importance of multidisciplinary, patient-centered care. They also discuss the growing role of CSF1R-targeted therapies, treatment selection, toxicity management, drug holidays, and practical approaches to optimizing long-term outcomes for patients living with TGCT. 

Topics Covered

• Understanding localized vs diffuse TGCT
• Biology of the CSF1/CSF1R pathway
• Diagnostic approaches and the role of MRI and biopsy
• Multidisciplinary care and shared decision-making
• Impact of TGCT on function, mobility, and quality of life
• Current and emerging CSF1R-targeted therapies
• Pexidartinib and vimseltinib: clinical considerations and toxicity management
• Response assessment beyond imaging
• Drug holidays, retreatment strategies, and long-term follow-up
• Future directions in TGCT research and treatment

Faculty

• William Tap, MD
• Emanuela Palmerini, MD, PhD

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.